{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:49:12Z","timestamp":1761871752293,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clml.2021.05.009","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T08:34:16Z","timestamp":1621845256000},"page":"694-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Posttransplant Lymphoproliferative Disorder After Solid Organ Transplant: A Heterogeneous, Aggressive Disorder"],"prefix":"10.1016","volume":"21","author":[{"given":"Laura","family":"McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roseann","family":"O\u2019 Doherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Enright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eoghan","family":"Dunlea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kelliher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Fortune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SW","family":"Maung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"Desmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derville","family":"O\u2019 Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Fadalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DG","family":"Connaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.05.009_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.009_bib0002","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","article-title":"Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors","volume":"54","author":"Dierickx","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.05.009_bib0003","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.21911","article-title":"Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States","volume":"86","author":"Quinlan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.05.009_bib0004","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/TP.0b013e318270bc7b","article-title":"Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database","volume":"94","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2021.05.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/230173","article-title":"Post-transplant lymphoproliferative disorders","author":"Ibrahim","year":"2012","journal-title":"Adv Haematol"},{"key":"10.1016\/j.clml.2021.05.009_bib0006","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2021.05.009_bib0007","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2021.05.009_bib0008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-017-0087-0","article-title":"Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients","volume":"6","author":"Bishnoi","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2021.05.009_bib0009","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/cncr.31339","article-title":"Impact of the posttransplant lymphoproliferative disorder subtype on survival","volume":"124","author":"Koff","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.009_bib0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0973-1482.95176","article-title":"Bone marrow involvement by lymphoproliferative disorders after renal transplantation: PTLD. Int. Survey","volume":"8","author":"Izadi","year":"2012","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.clml.2021.05.009_bib0011","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bjh.15263","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"180","author":"DeStefano","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.05.009_bib0012","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2021.05.009_bib0013","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1086\/424447","article-title":"New developments in the diagnosis and management of post-transplantation lymphoproliferative disorders in solid organ transplant recipients","volume":"39","author":"Preiksaitis","year":"2004","journal-title":"Clinical Inf Dis"},{"key":"10.1016\/j.clml.2021.05.009_bib0014","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for post-transplantation lymphoproliferative disorder","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2021.05.009_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/10428190400012011","article-title":"Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era","volume":"46","author":"Ghobrial","year":"2005","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.clml.2021.05.009_bib0016","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter, phase II trial","volume":"35","author":"Trappe","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.009_bib0017","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","article-title":"Treatment of PTLD with Rituximab or chemotherapy","volume":"6","author":"Elstrom","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2021.05.009_bib0018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1432-2277.2006.00284.x","article-title":"Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab","volume":"19","author":"Svoboda","year":"2006","journal-title":"Transplant Int"},{"key":"10.1016\/j.clml.2021.05.009_bib0019","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1046\/j.1365-2141.2003.04705.x","article-title":"Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carbiplatin and etoposide","volume":"123","author":"Oertel","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.05.009_bib0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/2040620711412417","article-title":"Therapeutic options in post-transplant lymphoproliferative disorders","volume":"2","author":"Zimmermann","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2021.05.009_bib0021","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2021.05.009_bib0022","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-019-00518-8","article-title":"Front-line treatment of high grade B cell non-hodgkin lymphoma","volume":"14","author":"Kesavan","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2021.05.009_bib0023","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/ndt\/gfv260","article-title":"Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients","volume":"30","author":"Taylor","year":"2015","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:58Z","timestamp":1761871078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2152265021001968"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posttransplant Lymphoproliferative Disorder After Solid Organ Transplant: A Heterogeneous, Aggressive Disorder","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}